Table 1.
Cohort Descriptive Characteristics
| n | % | |
|---|---|---|
| High-Risk Pathology | ||
| T2 m+ | 112 | 45.4% |
| T3 m+ | 76 | 30.8% |
| T3 m− | 49 | 19.8% |
| T4 m+ | 8 | 3.2% |
| T4 m− | 1 | 0.4% |
| Txm+ | 0 | 0% |
| T4 m− | 0 | 0% |
| T3mx | 1 | 0.4% |
| iPSA | ||
| <10 | 175 | 70.8% |
| ≥10 to <20 | 57 | 23.1% |
| ≥20 | 13 | 5.3% |
| Unknown | 2 | 0.8% |
| Pathologic Gleason Grade | ||
| 6 | 46 | 18.6% |
| 7 | 153 | 61.9% |
| ≥8 | 48 | 19.5% |
| Pathological T-stage | ||
| T2 | 112 | 45.4% |
| T3 | 126 | 51.0% |
| T4 | 9 | 3.6% |
| Margin Status | ||
| Positive | 196 | 79.4% |
| Negative | 50 | 20.2% |
| Unknown | 1 | 0.4% |
| Surgical Type | ||
| Retropubic | 141 | 57.1% |
| Robotic | 98 | 39.7% |
| Unknown | 8 | 3.2% |
| Median Time of 1st Post-op PSA taken | 3.0 months | |
| Median # of PSAs taken | 4 (1–16) | |
| Median Follow-up | 44 months | |
| 5-year biochemical recurrence free survival (PSA ≥0.2) | 54% | |
| Median Time to BCR (PSA ≥0.2 ng/mL) | 86 months | |